Optimer inhibitors deliver the hot start control your high-fidelity enzymes need. Download the application note to learn how: Optimer inhibits both polymerase and exonuclease activity at ambient temperature and…
Choosing the right affinity ligand is the key to success in cell and tissue applications—especially for effective cell targeting and reliable biomarker discovery. Lack of reagent compatibility with cell…
Cell screens can be included in the aptamer discovery process, providing built-in validation for your binder. In most affinity ligand discovery processes, whether for…
Using multiple discovery methods in aptamer development provides better binders. Learn why multiple discovery methods are important, which is right for you and how they can be combined for…
Uncover disease-defining biomarkers by starting with cellular phenotypes, not predetermined targets. Why do we need new biomarkers? Traditional biomarker discovery relies on testing predetermined targets…
The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…
Rapid and reversible aptamer binding is helping to build new in vivo biosensors that will change the way we diagnose and treat disease. Dr Netz Arroyo is an Assistant Professor…
Watch as Dr David Bunka, Aptamer Group CTO, and Dr Edgar Goluch, QSM Diagnostics CEO, discuss the application of Optimer binders to the development of novel rapid diagnostics. See how…
Novel diagnostic platforms are bringing possibilities for improved patient care and reduced healthcare costs. We spoke with Dr Edgar Goluch, the CEO and founder of QSM Diagnostics,
Presented at SLAS 2021 by collaborators at Boston University showing Aptamer Group’s COVID-19 Optimers used in the high content imager platform, MuviCyte, to help further our understanding of viruses…
